Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Compassionate Use of Remdesivir in Covid-19

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  2. Soluble Urokinase Receptor and Acute Kidney Injury

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Erythropoietin in Preterm Infants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Association between Mental Disorders and Subsequent Medical Conditions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Interstitial lung abnormalities in people with HIV infection and uninfected controls

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genetic variation at PPP1R3B increases hepatic CT attenuation and interacts with prandial status on plasma glucose

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Impact of glucose on risk of dementia: Mendelian randomisation studies in 115,875 individuals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Repositioning of the global epicentre of non-optimal cholesterol

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • AKCEA-APO(a)-LRx Study Investigators
Vis graf over relationer

BACKGROUND: Lipoprotein(a) levels are genetically determined and, when elevated, are a risk factor for cardiovascular disease and aortic stenosis. There are no approved pharmacologic therapies to lower lipoprotein(a) levels.

METHODS: We conducted a randomized, double-blind, placebo-controlled, dose-ranging trial involving 286 patients with established cardiovascular disease and screening lipoprotein(a) levels of at least 60 mg per deciliter (150 nmol per liter). Patients received the hepatocyte-directed antisense oligonucleotide AKCEA-APO(a)-LRx, referred to here as APO(a)-LRx (20, 40, or 60 mg every 4 weeks; 20 mg every 2 weeks; or 20 mg every week), or saline placebo subcutaneously for 6 to 12 months. The lipoprotein(a) level was measured with an isoform-independent assay. The primary end point was the percent change in lipoprotein(a) level from baseline to month 6 of exposure (week 25 in the groups that received monthly doses and week 27 in the groups that received more frequent doses).

RESULTS: The median baseline lipoprotein(a) levels in the six groups ranged from 204.5 to 246.6 nmol per liter. Administration of APO(a)-LRx resulted in dose-dependent decreases in lipoprotein(a) levels, with mean percent decreases of 35% at a dose of 20 mg every 4 weeks, 56% at 40 mg every 4 weeks, 58% at 20 mg every 2 weeks, 72% at 60 mg every 4 weeks, and 80% at 20 mg every week, as compared with 6% with placebo (P values for the comparison with placebo ranged from 0.003 to <0.001). There were no significant differences between any APO(a)-LRx dose and placebo with respect to platelet counts, liver and renal measures, or influenza-like symptoms. The most common adverse events were injection-site reactions.

CONCLUSIONS: APO(a)-LRx reduced lipoprotein(a) levels in a dose-dependent manner in patients who had elevated lipoprotein(a) levels and established cardiovascular disease. (Funded by Akcea Therapeutics; ClinicalTrials.gov number, NCT03070782.).

OriginalsprogEngelsk
TidsskriftThe New England journal of medicine
Vol/bind382
Udgave nummer3
Sider (fra-til)244-255
Antal sider12
ISSN0028-4793
DOI
StatusUdgivet - 16 jan. 2020

Bibliografisk note

Copyright © 2020 Massachusetts Medical Society.

ID: 59310635